

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 January 2025 (16.01.2025)



(10) International Publication Number
WO 2025/014830 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) A61P 35/00 (2006.01)

A61K 47/65 (2017.01)

(21) International Application Number:

PCT/US2024/036950

(22) International Filing Date:

05 July 2024 (05.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/512,428	07 July 2023 (07.07.2023)	US
63/606,519	05 December 2023 (05.12.2023)	US
63/558,540	27 February 2024 (27.02.2024)	US
63/640,733	30 April 2024 (30.04.2024)	US
63/667,649	03 July 2024 (03.07.2024)	US

(71) Applicant: **SOLVE THERAPEUTICS, INC.** [US/US];
11045 Roselle Street, Suite 130, San Diego, California
92121 (US).

(72) Inventors: **LANNUTTI, Brian**; 11045 Roselle Street,
Suite 130, San Diego, California 92121 (US). **WATKINS,
Jeff**; 11045 Roselle Street, Suite 130, San Diego, California
92121 (US). **JESSEN, Katti**; 11045 Roselle Street, Suite
130, San Diego, California 92121 (US).

(74) Agent: **MARTINEZ, Jose** et al.; WILSON SONSINI
GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto,
California 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

WO 2025/014830 A1

(54) Title: CONJUGATES OF DRUG UNITS AND TARGETING UNITS AND PRECURSOR COMPOUNDS THEREOF



(57) Abstract: Provided herein is a Drug-Linker of Formula (I) or a pharmaceutically acceptable salt thereof, wherein D is a drug unit, K1 is selected from (i) a peptide unit, (ii) an oligosaccharide, and (iii) a polyether, and M1 is a group which can react with a ligand to form a connector unit. Such compounds can be useful as anti-cancer agents.